Maternal Treatment With Captopril Persistently Alters Gut-Brain Communication and Attenuates Hypertension of Male Offspring

Hypertension. 2020 May;75(5):1315-1324. doi: 10.1161/HYPERTENSIONAHA.120.14736. Epub 2020 Mar 23.

Abstract

Maternal-fetal crosstalk has been implicated in long-term control of the health of offspring, including transgenerational hypertension. However, current knowledge is limited regarding maternal influences on the gut and its microbiome in blood pressure control in offspring. Therefore, the current study was designed to test the hypothesis that maternal factors influence the gut-brain axis impacting hypertension in offspring. We elected to use captopril, an antihypertensive angiotensin-converting enzyme inhibitor that possesses antibacterial properties, for the study. Pregnant female spontaneously hypertensive rats and normotensive Wistar Kyoto rats were treated with captopril water (100 mg/[kg·day]) or sterile water throughout pregnancy and lactation. At weaning, the pups from dams drinking sterile water were continued with sterile water until 12 weeks of age. The male pups from dams drinking captopril water were divided at weaning into 2 groups: offspring drinking captopril water and offspring withdrawn from captopril water, then drinking sterile water until 12 weeks of age. Captopril changed gut microbiota of spontaneously hypertensive rat dams, and some of these changes were reflected in their 12-week-old male offspring. These 12-week-old spontaneously hypertensive rat male offspring exposed to captopril via dams demonstrated persistently decreased systolic blood pressure, decreased number of activated microglia and neuroinflammation, as well as improvement of gut inflammation and permeability. Therefore, maternal captopril treatment improves the dysregulated gut-brain axis in spontaneously hypertensive rat male offspring, providing conceptual support that targeting the gut-brain axis via the mother may be a viable strategy for control of hypertension in the offspring.

Keywords: captopril; hypertension; inflammation; microbiota; microglia.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / pharmacokinetics
  • Antihypertensive Agents / pharmacology*
  • Antihypertensive Agents / therapeutic use
  • Bacterial Proteins / antagonists & inhibitors*
  • Brain / embryology
  • Brain / physiopathology*
  • Captopril / administration & dosage
  • Captopril / pharmacokinetics
  • Captopril / pharmacology*
  • Captopril / therapeutic use
  • Colon / metabolism
  • Colon / microbiology
  • Colon / pathology
  • Dysbiosis / complications
  • Dysbiosis / microbiology*
  • Dysbiosis / pathology
  • Female
  • Gastrointestinal Microbiome / drug effects*
  • Hypertension / drug therapy
  • Hypertension / etiology
  • Hypertension / prevention & control*
  • Lactation
  • Male
  • Maternal-Fetal Exchange*
  • Norepinephrine / biosynthesis
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy
  • Prenatal Exposure Delayed Effects*
  • RNA / biosynthesis
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Sympathetic Nervous System / metabolism
  • Sympathetic Nervous System / physiopathology
  • Tight Junction Proteins / biosynthesis
  • Tight Junction Proteins / genetics
  • Weaning

Substances

  • Antihypertensive Agents
  • Bacterial Proteins
  • Tight Junction Proteins
  • RNA
  • Captopril
  • Norepinephrine